Clinical Oral Investigations

, Volume 23, Issue 2, pp 921–928 | Cite as

Effect of intracanal medicaments on matrix metalloproteinase-9 and vasoactive intestinal peptide secretion in periapical lesions of re-treated canals: a randomized controlled clinical study

  • Mine Büker Özdemir
  • Ertuğrul KarataşEmail author
  • Mevlüt Albayrak
  • Yasin Bayır
Original Article



The aim of this study was to evaluate the effect of calcium hydroxide (Ca[OH]2) and chlorhexidine (CHX) gel on matrix metalloproteinase-9 (MMP-9) and vasoactive intestinal peptide (VIP) secretion in periapical lesions.

Materials and methods

A total of 60 patients were randomly divided into two groups that were to receive different medications. Pre-and post-treatment samples were collected from the interstitial fluid of periapical lesions using sterile paper points. VIP and MMP-9 levels were measured by enzyme-linked immunosorbent assay kits, and the data were statistically analyzed.


Gender and smoking habits had no effect on the pre- and post-treatment VIP and MMPs levels. Intragroup analyses revealed that in the Ca(OH)2 group, the post-treatment VIP level was found to be significantly higher than the pre-treatment VIP level. In the CHX group, the post-treatment MMP-9 level was significantly higher than the pre-treatment MMP-9 level.


According to the results of the present study, the type of the medication affected the amount of periapical VIP and MMP-9 secretion.

Clinical relevance

VIP is a neuropeptide that promotes new bone formation. Thus, intracanal Ca(OH)2 medication may accelerate the repair process of bone tissue.


Ca(OH)2 CHX gel Vasoactive intestinal peptide Matrix metalloproteinase-9 



Manuscript in Lieu of Thesis

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the ethical committee of the Faculty of Dentistry, Atatürk University (decision no. 2017-28).

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Nair PN (2004) Pathogenesis of apical periodontitis and the causes of endodontic failures. Crit Rev Oral Biol Med 15(6):348–381Google Scholar
  2. 2.
    Marton IJ, Kiss C (2014) Overlapping protective and destructive regulatory pathways in apical periodontitis. J Endod 40(2):155–163Google Scholar
  3. 3.
    Colic M et al (2006) Correlation between phenotypic characteristics of mononuclear cells isolated from human periapical lesions and their in vitro production of Th1 and Th2 cytokines. Arch Oral Biol 51(12):1120–1130Google Scholar
  4. 4.
    De la Fuente M, Delgado M, Gomariz RP (1996) VIP modulation of immune cell functions. Adv Neuroimmunol 6(1):75–91Google Scholar
  5. 5.
    Uddman R, Björlin G, Möller B, Sundler F (1980) Occurrence of VIP nerves in mammalian dental pulps. Acta Odontol Scand 38(5):325–328Google Scholar
  6. 6.
    Lundberg P, Lie A, Bjurholm A, Lehenkari PP, Horton MA, Lerner UH, Ransjö M (2000) Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts. Bone 27(6):803–810Google Scholar
  7. 7.
    Mauviel A (1993) Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 53(4):288–295Google Scholar
  8. 8.
    Bosman FT, Stamenkovic I (2003) Functional structure and composition of the extracellular matrix. J Pathol 200(4):423–428Google Scholar
  9. 9.
    Marton IJ, Kiss C (2000) Protective and destructive immune reactions in apical periodontitis. Oral Microbiol Immunol 15(3):139–150Google Scholar
  10. 10.
    Lin LM, Huang GT, Rosenberg PA (2007) Proliferation of epithelial cell rests, formation of apical cysts, and regression of apical cysts after periapical wound healing. J Endod 33(8):908–916Google Scholar
  11. 11.
    Carneiro E, Menezes R, Garlet GP, Garcia RB, Monteiro Bramante C, Figueira R, Sogayar M, Mauro Granjeiro J (2009) Expression analysis of matrix metalloproteinase-9 in epithelialized and nonepithelialized apical periodontitis lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107(1):127–132Google Scholar
  12. 12.
    Pereira Faustino IS, Azevedo RS, Takahama A Jr (2016) Metalloproteinases 2 and 9 immunoexpression in periapical lesions from primary endodontic infection: possible relationship with the histopathological diagnosis and the presence of pain. J Endod 42(4):547–551Google Scholar
  13. 13.
    Campos K, Gomes CC, Farias LC, Silva RM, Letra A, Gomez RS (2016) DNA methylation of MMP9 is associated with high levels of MMP-9 messenger RNA in periapical inflammatory lesions. J Endod 42(1):127–130Google Scholar
  14. 14.
    Ma T et al (2017) Correlation of matrix metalloproteinase-9 polymorphisms with chronic periodontitis in Uygur adults. Zhonghua Kou Qiang Yi Xue Za Zhi 52(6):360–366Google Scholar
  15. 15.
    Estrela C, Holland R, Estrela CRA, Alencar AHG, Sousa-Neto MD, Pécora JD (2014) Characterization of successful root canal treatment. Braz Dent J 25(1):3–11Google Scholar
  16. 16.
    Portenier I et al (2005) The susceptibility of starved, stationary phase, and growing cells of Enterococcus faecalis to endodontic medicaments. J Endod 31(5):380–386Google Scholar
  17. 17.
    Lakhani AA et al (2017) Efficacy of triple antibiotic paste, moxifloxacin, calcium hydroxide and 2% chlorhexidine gel in elimination of E. Faecalis: an in vitro study. J Clin Diagn Res 11(1):ZC06–ZC09Google Scholar
  18. 18.
    Martinho FC et al (2017) Clinical comparison of the effectiveness of 7- and 14-day intracanal medications in root canal disinfection and inflammatory cytokines. Clin Oral Investig 22:523–530Google Scholar
  19. 19.
    Gendron R et al (1999) Inhibition of the activities of matrix metalloproteinases 2, 8, and 9 by chlorhexidine. Clin Diagn Lab Immunol 6(3):437–439Google Scholar
  20. 20.
    Khan AA, Sun X, Hargreaves KM (2008) Effect of calcium hydroxide on proinflammatory cytokines and neuropeptides. J Endod 34(11):1360–1363Google Scholar
  21. 21.
    Martinho FC, Nascimento GG, Leite FRM, Gomes APM, Freitas LF, Camões ICG (2015) Clinical influence of different intracanal medications on Th1-type and Th2-type cytokine responses in apical periodontitis. J Endod 41(2):169–175Google Scholar
  22. 22.
    Paula-Silva FW, da Silva LA, Kapila YL (2010) Matrix metalloproteinase expression in teeth with apical periodontitis is differentially modulated by the modality of root canal treatment. J Endod 36(2):231–237Google Scholar
  23. 23.
    Goetzl EJ, Banda MJ, Leppert D (1996) Matrix metalloproteinases in immunity. J Immunol 156(1):1–4Google Scholar
  24. 24.
    Corotti MV, Zambuzzi WF, Paiva KBS, Menezes R, Pinto LC, Lara VS, Granjeiro JM (2009) Immunolocalization of matrix metalloproteinases-2 and -9 during apical periodontitis development. Arch Oral Biol 54(8):764–771Google Scholar
  25. 25.
    Pozo D, Delgado M, Martínez C, Guerrero JM, Leceta J, Gomariz RP, Calvo JR (2000) Immunobiology of vasoactive intestinal peptide (VIP). Immunol Today 21(1):7–11Google Scholar
  26. 26.
    Adl A, Motamedifar M, Shams MS, Mirzaie A (2015) Clinical investigation of the effect of calcium hydroxide intracanal dressing on bacterial lipopolysaccharide reduction from infected root canals. Aust Endod J 41(1):12–16Google Scholar
  27. 27.
    Tanomaru JM et al (2003) Effect of different irrigation solutions and calcium hydroxide on bacterial LPS. Int Endod J 36(11):733–739Google Scholar
  28. 28.
    Martinho FC, Teixeira FFC, Cardoso FGR, Ferreira NS, Nascimento GG, Carvalho CAT, Valera MC (2016) Clinical investigation of matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, and matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase complexes and their networks in apical periodontitis. J Endod 42(7):1082–1088Google Scholar
  29. 29.
    Caviedes-Bucheli J, Azuero-Holguín MM, Moreno GC, González IL, Mateu E, Salazar JF, Munoz HR (2007) Vasoactive intestinal peptide receptor expression in chronic periapical lesions. Int Endod J 40(7):521–525Google Scholar
  30. 30.
    Jiang J, Zuo J, Chen SH, Holliday LS (2003) Calcium hydroxide reduces lipopolysaccharide-stimulated osteoclast formation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95(3):348–354Google Scholar
  31. 31.
    Vassiliou E, Jiang X, Delgado M, Ganea D (2001) TH2 lymphocytes secrete functional VIP upon antigen stimulation. Arch Physiol Biochem 109(4):365–368Google Scholar
  32. 32.
    Ferraz CC et al (2001) In vitro assessment of the antimicrobial action and the mechanical ability of chlorhexidine gel as an endodontic irrigant. J Endod 27(7):452–455Google Scholar
  33. 33.
    Buck RA et al (2001) Detoxification of endotoxin by endodontic irrigants and calcium hydroxide. J Endod 27(5):325–327Google Scholar
  34. 34.
    Kato Y, Nakayama Y, Umeda M, Miyazaki K (1992) Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem 267(16):11424–11430Google Scholar
  35. 35.
    Zehnder M, Wegehaupt FJ, Attin T (2011) A first study on the usefulness of matrix metalloproteinase 9 from dentinal fluid to indicate pulp inflammation. J Endod 37(1):17–20Google Scholar
  36. 36.
    Manicone AM, McGuire JK (2008) Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 19(1):34–41Google Scholar
  37. 37.
    Rodig T et al (2010) Efficacy of different irrigants in the removal of calcium hydroxide from root canals. Int Endod J 43(6):519–527Google Scholar
  38. 38.
    Violich DR, Chandler NP (2010) The smear layer in endodontics—a review. Int Endod J 43(1):2–15Google Scholar
  39. 39.
    Chockattu SJ, Deepak BS, Goud KM (2017) Comparison of efficiency of ethylenediaminetetraacetic acid, citric acid, and etidronate in the removal of calcium hydroxide intracanal medicament using scanning electron microscopic analysis: an in-vitro study. J Conserv Dent 20(1):6–11Google Scholar
  40. 40.
    Hulsmann M, Heckendorff M, Lennon A (2003) Chelating agents in root canal treatment: mode of action and indications for their use. Int Endod J 36(12):810–830Google Scholar
  41. 41.
    Chandra SS, Miglani R, Srinivasan MR, Indira R (2010) Antifungal efficacy of 5.25% sodium hypochlorite, 2% chlorhexidine gluconate, and 17% EDTA with and without an antifungal agent. J Endod 36(4):675–678Google Scholar
  42. 42.
    Ordinola-Zapata R, Bramante CM, Cavenago B, Graeff MSZ, Gomes de Moraes I, Marciano M, Duarte MAH (2012) Antimicrobial effect of endodontic solutions used as final irrigants on a dentine biofilm model. Int Endod J 45(2):162–168Google Scholar
  43. 43.
    Arias-Moliz MT, Ferrer-Luque CM, Espigares-Rodríguez E, Liébana-Ureña J, Espigares-García M (2008) Bactericidal activity of phosphoric acid, citric acid, and EDTA solutions against Enterococcus faecalis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106(2):e84–e89Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Mine Büker Özdemir
    • 1
  • Ertuğrul Karataş
    • 1
    Email author
  • Mevlüt Albayrak
    • 2
  • Yasin Bayır
    • 3
  1. 1.Department of Endodontics, Faculty of DentistryAtaturk UniversityErzurumTurkey
  2. 2.Erzurum High Vocational School of HealthAtaturk UniversityErzurumTurkey
  3. 3.Department of BiochemistryFaculty of Pharmacy Ataturk UniversityErzurumTurkey

Personalised recommendations